INTERVIEW WITH josh ofman, md, mshs

Footer Background_v2 copy

josh-ofman-1Joshua J. Ofman, MD, MSHS, is the Senior Vice President, Global Value, Access and Policy at Amgen ensuring the integration of reimbursement needs into the product development and commercialization process. In prior roles, Dr. Ofman was an academic gastroenterologist at Cedars-Sinai Health System and Senior Vice President of Zynx Health Inc., focused on evidence-based clinical information for quality improvement and reimbursement, and health economics strategy for life sciences companies. Dr. Ofman received his advanced medical training in Gastroenterology from UCLA and his Health Services Research training from the RAND/UCLA/VA program.

Key Takeaways

  • The biopharmaceutical industry has a vested interest in fruitful patient centric collaborations to drive our attention towards the most pressing health issues for which we can make a positive impact.
  • Developing substantive 1:1 relationships with key stakeholders is crucial to open up the conversation to high value collaborations.
  • The leadership of all stakeholder organizations needs to demonstrate their commitment to collaboration, or else it will be seen as just a business tactic and progress will be stalled.

Can you tell us about your role as SVP, Global Value, Access and Policy at Amgen?

I oversee the work we do on the pipeline to ensure we are embedding payer-thinking into the way that we develop and commercialize our products on a global scale. I oversee our government affairs activities outside of the U.S., our health policy activities, our global advocacy activities, and our value-based partnerships with payers and governments around the world. Finally, I oversee the global pricing activities, including the launch price policies for our new products. I also play a role on Amgen’s Portfolio Governance Committee, Global Commercial Committee and Deal Review Committee where, with my colleagues, we review the commercial forecast and strategic plans, business development assumptions and plans, and the portfolio strategy which ultimately reports up to our CEO.

Can you elaborate what is meant by “embedding payer-thinking” into your process?

As an example, let’s say we’ve just established the proof of concept of a potential drug for rheumatoid arthritis. There are a lot of ways you could develop that molecule. Our team has a keen understanding of the value drivers at play for patients, payers, and society more broadly. We take this a layer deeper to understand how payers think about the disease, the competitors, how the formularies work, what the prices are in the market and what the access restrictions are around the world. With this information in mind, we can develop a research program that addresses the biggest issues around this new drug. For example, if we need to demonstrate that the drug is going to work in a particular sub-population of patients, we may do a different subset of trials to test the drug, or if we need to demonstrate breakthrough or best-in-class effectiveness, then we may need to take the risk of a comparative trial with one or more agents and actually measure resource utilization on the trials. We may find that a key value driver is quality of life and productivity, and thus need to develop novel instruments to measure that in the studies. For novel agents, we may need to design trials with endpoints that matter most to patients, and that will demonstrate the value proposition to support our pricing. Lastly, we need to continue to explore how best to “embed payer-thinking” when developing our products to help inform our clinical development programs, the comparators, the endpoints assessed, and even the way the study is powered and the data are analyzed, keeping both regulatory and payer requirements top of mind.

What is Amgen’s role in the broader health ecosystem?

What I believe is unique about Amgen’s process is that we think very broadly and holistically about our role in the health ecosystem. It certainly hasn’t always been this way, but the shift that we’ve made in thinking throughout the last five years has been quite a departure from how things used to be done. Traditionally, biopharmaceutical companies have been a supplier into the health ecosystem. We are becoming an integral part of the broader health ecosystem comprised of providers (the delivery system), payers (the payment system), and intermediaries (the wholesalers, the distributors, the PBMs). Amgen is making efforts to think much more holistically about how we can partner collaboratively with all of these players in the healthcare ecosystem to drive better outcomes, improve population health, and deliver more value to the system.

How do you encourage a collaborative mindset internally within Amgen?

Over the last five years, our payer teams have led the company into the realm of value-based partnerships and innovative payment models. As part of a broader corporate transformation, we have really instituted a “Call to Action” to create some urgency in the company around how we have to step up to become a more integrative, collaborative partner in the healthcare system. I’ve presented at leadership meetings across the company and to the CEO staff to try to stimulate the company to recognize the importance of becoming a more integrated partner and collaborator in our complex healthcare ecosystem. Usually, my pitch includes the following:

“The healthcare system is under a period of dynamic change where issues of affordability, cost, and value are rising to the forefront. The system is burdened by a tremendous financial strain. The main culprit is the rising cost of disease and the aging population. The solution to that problem, in many respects, are innovative biopharmaceuticals. But too often we’re seen as the problem, and so we have to change the conversation within the ecosystem to recognize that innovative biopharmaceuticals are part of that solution, and in order to get that done we have to become an integrated, collaborative partner in this health ecosystem so that we’re not seen simply as a supplier.”

How has Amgen begun to make the shift from being viewed as a supplier to a collaborator?

Through its Patient-first model, Amgen is committed to being a productive partner in collaboration with all stakeholders to manage rising healthcare costs and reduce human and financial burden of serious disease. The first step is to build substantive and trusted relationships. We engage with some of the key thought leaders, think tanks, policy makers, and large employer coalitions in the country and ex-U.S. as well. We’re involved with the Duke Margolis Center, the Schaeffer Center for Health Policy and Economics, the International Consortium for Health Outcomes Measurement and the critical government agencies like CMS, and PCORI among others. The next step is to begin to develop partnerships with all the various stakeholders, which we’ve begun to do already with various payer and employer groups in the U.S. and institutions and governments ex-U.S. Ultimately, we’d like to bring together multiple parties at the same time to drive some collaborative partnerships. That’s really the next step in the evolution of where we’re headed. Until then, we are learning about each of the stakeholders in 1:1 relationships, and how we may work together most effectively to improve patient care.

The best hope for patients in the fight against serious disease are innovative medicines. Ensuring appropriate access to these medicines increasingly requires a comprehensive set of solutions and, among these solutions, value-based partnerships are showing great promise. The legislative and regulatory environment is complex, and Amgen is steadily increasing our expertise, bandwidth, and capabilities in this space. As we look ahead though, refinements to both legislation and policies could help increase and facilitate both the number and types of these partnerships and help support stakeholders realize the potential that value-based partnerships can bring to the healthcare system.

Could you provide an example of a value-based partnership between Amgen and another health ecosystem player?

We recently sent out a press release about a 3-year collaborative partnership with Humana, one of the largest payers in the country. Humana was a very logical partner because we have a shared interest in population health, they have always been a leader in public health, and have an organization within Humana that is focused on how to measure and collect data in their population. All those things together made them a terrific choice for a potential partnership. We reached out to their senior leadership team to discuss opportunities to work together. As you may know, there’s a lot of skepticism from payers about our industry’s motives. We had to work to gain their trust, so that they could recognize our sincere intention of identifying mutual areas of interest. The first thing we did was pull together a small group of executives to open up the conversation and get to know one another. We had to be sure to have the right people around the table and be very transparent to demonstrate our mindset of collaboration. Once we broke through that initial barrier of getting to know each other’s points of view and aligning on mutual goals, we held a series of subsequent meetings to begin generating creative ideas and fleshing them out. We are now working with them on 7 different projects to improve the quality and efficient of care of the populations we serve.

Could you share some of the collaborative solutions you’re working on?

With Humana, we are still in the early stages of identifying opportunities. However, I can share some interesting things we’ve been doing with United Healthcare, another major payer in the health industry. With United Healthcare, we have a great partnership around patients who have been hospitalized with fractures. Over 50% of U.S. patients who have had a hip fracture never get tested, diagnosed, or treated for osteoporosis. Osteoporosis is so common, and when patients fracture and are hospitalized, they often end up in nursing homes and their quality of life suffers. We worked with United to put together an educational intervention program directed towards patients and physicians to improve diagnosis and treatment rates.

How did you identify United as a potential collaborative partner, and who were the key stakeholders involved?

For the past 5 years, Amgen has developed deep, collaborative partnerships with some of the payers. Our partnership with United grew out of our long-standing relationship with Optum Insights, the health information technology and services firm that is part of UnitedHealth Group. Routinely we meet with their medical leadership team to talk about their interests and the work going on within their health plan and their health system clients. In one of those meetings several years ago, we discovered that osteoporosis was one of their focus areas, which is one that we share as well. Once we identified that as a mutual area of interest, we brainstormed a couple of ideas for how we could improve care in that area, and that’s what resulted in the collaboration.

What are some obstacles that may hinder developing collaborative solutions with other sectors?

It’s critical for the success of these partnerships to keep the focus of the conversation on the common ground of population health. By doing so, the parties interests remain aligned on a shared goal as opposed to enhancing one organization or the other. For Amgen, we engage in partnerships where we feel we can make a difference on population health as opposed to a focusing only on Amgen products. With United, our collective interests were well-aligned on the patient. When we run into situations where the financial interests are the primary focus or significantly divergent, we choose not to pursue. That rarely happens, though – we are almost always able to find common ground with our potential partners and are able to work together.

What would you say are “lessons learned” from your experiences developing collaborative partnerships?

The leadership of both organizations needs to be involved. If it’s seen as just a business tactic, these collaborations tend to stall or fall apart. If the right leadership is involved, and there’s the right level of organizational commitment, then I think you can make some great progress. The other thing is that the gravity of organizations to continue to maintain the “status quo” is very strong, and it takes a lot of resilience to move the organization away from that mentality. One of my mentors when I first came to Amgen, Craig Brooks, used to coach me about being too impatient and that the change I was trying to effect would take much longer than I thought. He was right. What I thought we could change in two years took four, and what I thought would take four took seven. It can certainly happen, but you really need resilience, passion, patience, and commitment to the vision in order to impact real and sustainable change.


View our other HELM Q&A Interviews:


Poonam Alaigh, MD, Remedy Partners, Inc.

Read More

Poonam Alaigh, MD, MSHCPM, FACP, is the Executive Vice President of Commercial Business at Remedy Partners, Inc., an organization focused on mobilizing payment reform by creating software and services that enable payers, employers, and at-risk providers to organize and finance healthcare delivery around a patient’s episode of care. Dr. Alaigh was previously the Acting Under Secretary for the U.S. Department of Veterans Affairs (VA), where she directed a healthcare system with an annual budget of over $70 billion and over 300K employees, overseeing the delivery of care to more than 9 million enrolled veterans.

Read More


Andrew Baskin, MD, and Mohamed Diab, MD, Aetna

Read More

Andrew-Baskin-headshotAndrew Baskin, MD, is Aetna’s Vice President, National MedicalDirector for Quality and Clinical Policy and served as the Interim Chief Medical Officer (in 2014). He works on initiatives to measure and improve quality of care, the provision of evidence based care, quality measurement implementation and public reporting, health plan accreditation, and the establishment of performance based networks. Additionally, Andy partners with others to help establish programs which create incentives for more effective and efficient care, influence and assure compliance with healthcare reform regulations, develop products to improve affordability and quality of care, and promote payment reform.

Mohamed Diab, MD, Vice President of Provider Transformation leads population health management at Aetna. His focus is on providers as they transform their care delivery to achieve the “Triple Aim” by improving quality of care and reducing unnecessary cost. Mohamed has more than 25 years of experience as a provider as well as an executive in the payer and consulting industries. He has a background in medical management, pharmacy benefit management, clinical informatics and cost management programs.

Read More


Tanisha Carino, Ph.D.,

Read More

Tanisha Carino, Ph.D., serves as Vice President, U.S. public policy at GSK, which is committed to helping people do more, feel better and live longer. In her role, Dr. Carino promotes public policies in the best interest of patients and the public’s health. Prior to GSK, Tanisha served as Executive VP at Avalere Health, a strategic health care advisory company, where she oversaw advisory and research services to the nation’s leading life sciences companies. Dr. Carino brings over 15 years of experience in consulting, management, health policy and strategy development across government, industry and academia. She is a recognized thought leader in the evolving U.S. regulatory environment, market access and commercial trends, as well as health technology and evidence-based medicine.

Read More


David Carmouche, MD, Ochsner Health System & Ochsner Health Network

Read More

David Carmouche, MD, is Senior Vice President of Ochsner Health System and President of Ochsner Health Network in Louisiana. In his current role, David is responsible for clinical integration, population health strategies, development of a data and analytics infrastructure, care management, network administration and insurance product development. David joined Ochsner with 19 years of progressive healthcare leadership experience in medicine and operations. Before joining Ochsner, Dr. Carmouche served as the Executive Vice President of External Operations and Chief Medical Officer at Blue Cross Blue Shield of Louisiana in Baton Rouge where he successfully led important initiatives designed to organize care, improve quality, and increase affordability.

Read More


Carman Ciervo, DO, Jefferson Health New Jersey

Read More

Carman Ciervo, D.O., FACOFP, is the Executive Vice President and Chief Physician Executive at Jefferson Health New Jersey (JHNJ). As a member of the senior leadership team since 2010, Carman has played a key role in Jefferson Health of New Jersey’s continued growth and transformation, working directly on hospital and health system initiatives related to the employed-physician model, population health, and clinical excellence. He has also overseen the progressive growth of the Jefferson Health New Jersey (formerly Kennedy) Health Alliance, a consumer-friendly network of primary and specialty medical practices throughout southern New Jersey.

Read More


Bob Garrett, John Lloyd, and Patrick Young, Hackensack Meridian Health

Read More

Bob-Garrett-headshotRobert C. Garrett is Co-CEO of Hackensack Meridian Health, which has four hospitals ranked among the top 10 in New Jersey according to U.S. News & World Report – including No. 1 ranked Hackensack University Medical Center - more than any other network in the state. Robert focused on aggressive expansion of the Hackensack University Network before its merger with Meridian Health. As Co-CEO, Robert concentrates on innovation and leading partnerships, including launching New Jersey’s first private medical school with Seton Hall University and a historic partnership with Memorial Sloan Kettering Cancer Center.

John K. Lloyd is Co-CEO of Hackensack Meridian Health, one of the largest, most comprehensive health networks in New Jersey, which includes 13 hospitals, 28,000 team members, more than 6,000 physicians and over 140 patient care locations across the state. John has focused much of his career on developing a full continuum of care – long before national health care reform mandated such changes. As Co-CEO, John oversees all non-acute care hospital businesses, including population health and the foundations. John’s expertise and vision have helped the network meet and exceed the challenges of health care reform.

Patrick R. Young is president of Population Health for Hackensack Meridian Health, where he leads the Population Health division and is responsible for accelerating the development of strategic priorities related to health care reform; population health management; Meridian’s Medicare Shared Savings Accountable Care Organization; Hackensack Meridian Health Partners, Hackensack Meridian Health’s clinically integrated network; health insurance partnerships; as well as overseeing Managed Care.

Read More


Matthew Guy, Accelerated Transformation Associates

Read More

Matthew Guy, a health ecosystem convener, is President and Owner of Accelerated Transformation Associates, and specializes in clinical, community, and population health transformation. Through his work with ReThink Health, he provides great insights on his work to convene groups in systemic changes to positively impact the health of the populations within Sonoma Country, CA; Bend, OR; and Albequerque, NM.

Read More


Bob Hemker,
Palomar Health

Read More

Bob Hemker is the former (now retired) President and CEO of Palomar Health, a district health system serving the health needs of the largest health care district in the Northern San Diego region. In addition to three hospitals, namely Palomar Medical Center Escondido, Palomar Medical Center Downtown Campus, and Palomar Medical Center Poway, Palomar Health offers home health care, surgery, skilled nursing, ambulatory care, behavioral health services, wound care, community health education programs and Level II Trauma service. Bob has extensive experience managing the strategic, financial, and operational aspects of healthcare organizations, working closely with communities, physicians, and board representatives.

Read More


Roland Lyon, Kaiser Permanente (KP) of Colorado

Read More

Roland Lyon is president of Kaiser Permanente (KP) of Colorado, where he leads the state’s largest nonprofit health plan, providing healthcare to approximately 670,000 members in Denver/Boulder, Southern Colorado, Northern Colorado, and the mountain communities of Summit and Eagle counties. Lyon joined KP in 2002, initially based in California before coming to Colorado in 2006. His roles in California included vice president of consulting and capital planning in KP’s Northern California region, and vice president of strategic planning in KP’s national program offices.

Read More

Julie Miller-Phipps

Julie Miller-Phipps, Kaiser Foundation Hospitals and Health Plan in So. CA

Read More

Julie Miller-Phipps is the President of Kaiser Foundation Hospitals and Health Plan in Southern California, where in partnership with leaders of Southern California Permanente Medical Group she directs operations for the region’s 14 hospitals and 222 medical offices. Julie previously served as President of Kaiser Foundation Health Plan of Georgia where she was responsible for the delivery of health care needs to nearly 300,000 Kaiser Permanente members who are served through a network of 26 medical offices and specialty centers, as well as four contracted hospitals.

Read More


Donna Mills, Central Oregon Health Council

Read More

Donna Mills is the Executive Director of Central Oregon Health Council. The Council convenes stakeholders across the health ecosystem to create and implement programs in service to the mission of better health, better care, and better value for healthcare in the Central Oregon Region. As a seasoned healthcare professional with experience in leadership positions in healthcare, finance, and operating management, Donna has a proven track record recommending and executing business and financial solutions and initiatives, ultimately contributing to an organization’s financial results.

Read More


Josh Ofman, MD,

Read More

Joshua J. Ofman, MD, MSHS, is the Senior Vice President, Global Value, Access and Policy at Amgen ensuring the integration of reimbursement needs into the product development and commercialization process. In prior roles, Dr. Ofman was an academic gastroenterologist at Cedars-Sinai Health System and Senior Vice President of Zynx Health Inc., focused on evidence-based clinical information for quality improvement and reimbursement, and health economics strategy for life sciences companies. Dr. Ofman received his advanced medical training in Gastroenterology from UCLA and his Health Services Research training from the RAND/UCLA/VA program.

Read More


Barry Ostrowsky, RWJBarnabas

Read More

Barry H. Ostrowsky is President and Chief Executive Officer for RWJBarnabas Health, New Jersey’s largest not-for-profit integrated health care delivery system and the largest private employer in the state. Mr. Ostrowsky joined Saint Barnabas Medical Center in 1991 as Executive Vice President and General Counsel. He served in the same role at Barnabas Health, when the System was created in 1996. He assumed the title of President and Chief Operating Officer in 2010, and became President and Chief Executive Officer in January 2012. Prior, Mr. Ostrowsky was a Senior Partner in the law firm of Brach Eichler. He received a BA from Rutgers University and a JD from the University of Tennessee School of Law.

Read More


Bob Sachs, Ph.D.

Read More

We are thrilled to share our first in a series of interviews on Leading in Today’s Health Ecosystem. This month, we had the great pleasure of interviewing Bob Sachs, PhD, Talent Strategy Advisor, Executive Coach, and Advisory Board Chair for TLD Group, about the importance of developing leaders who have the capacity to work collaboratively across healthcare sectors to drive population health and reduce healthcare costs. Bob, formerly the VP of National Learning and Development at Kaiser Permanente and a national leader in integrated healthcare, works with organizations to enhance and integrate critical leadership talent strategies and systems, on learning strategy and governance.

Read More


Craig Samitt, MD, MBA,
Anthem, Inc.

Read More

Craig Samitt, MD, MBA, is the EVP and Chief Clinical Officer at Anthem, where he is responsible for establishing, leading, and executing overall clinical vision and strategy for Anthem, the second largest health insurer in the US. In this role, Craig leads all clinical operations and policy as well as Anthem’s diversification strategy, from payer as a benefit-management company to payer as partner, enabler, and convener. An internal medicine physician by training, Craig has worked across multiple sectors within the health ecosystem including providers, payers, and policy makers. His work specializes in turnaround management, growth of physician networks, enhancing integrated delivery systems, and diversifying health plans in competitive markets.

Read More


Lorie Shoemaker, DHA, RN, MSN, CHI - Texas Division

Read More

Lorie Shoemaker, DHA, RN, MSN, is the SVP and Chief Nursing Officer at CHI – Texas Division, where she is responsible for the oversight of the quality of nursing care and nursing practice across the acute and post-acute care continuum. Prior to joining CHI St. Luke’s Health, Dr. Shoemaker served in a variety of leadership roles over a 29-year career at Palomar Health in California, including the System Chief Nurse Executive. In this role, Dr. Shoemaker provided oversight for nursing care across the system that included three acute care hospitals, two skilled nursing facilities, as well as ambulatory and home health agencies.

Read More


Joe Wilkins, MBA, FACHE, Atlantic Health System

Read More

Joe Wilkins, MBA, FACHE, is the Senior Vice President, Chief Transformation Officer at Atlantic Health System. As a healthcare industry executive, Mr. Wilkins has repeatedly driven significant organizational transformations. Mr. Wilkins has dedicated his career to executive management and boardroom leadership within healthcare organizations. He strives to make a difference within our communities, to advance healthcare equity, innovation and transformation, while expanding access, affordability and improving the quality of healthcare and mental health services.

Read More